Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.60 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | AGXT | P21549 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3456220 | 1.00 | TAAR1 (0.60) | TAAR1IDO1AGXTSIGMAR1MAOB | |
| SCHEMBL3456094 | 0.98 | TAAR1 (0.62) | TAAR1IDO1AGXTSIGMAR1MAOB | |
| SCHEMBL19524669 | 0.90 | TAAR1 (0.65) | TAAR1IDO1AGXTSIGMAR1MAOB | |
| SCHEMBL552962 | 0.85 | TAAR1 (0.71) | TAAR1IDO1AGXTSIGMAR1 | |
| SCHEMBL28585404 | 0.84 | TAAR1 (0.59) | TAAR1IDO1AGXTSIGMAR1MAOB | |
| SCHEMBL30444743 | 0.84 | TAAR1 (0.59) | TAAR1IDO1AGXTSIGMAR1MAOB | |
| SCHEMBL16203114 | 0.84 | TAAR1 (0.59) | TAAR1IDO1AGXTSIGMAR1MAOB | |
| SCHEMBL7199505 | 0.84 | TAAR1 (0.69) | TAAR1IDO1AGXTSIGMAR1MAOB | |
| SCHEMBL5240585 | 0.83 | TAAR1 (0.68) | TAAR1IDO1AGXTSIGMAR1MAOB | |
| SCHEMBL19524577 | 0.83 | MAOB (0.54) | TAAR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2256107-A1 | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds as inhibitors of the beta-secretase (BACE) | Wyeth LLC (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20090012139-A1 | AMINO-5-[4-(DIFLUOROMETHOXY) PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012139-A1 | AMINO-5-[4-(DIFLUOROMETHOXY) PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012139-A1 | AMINO-5-[4-(DIFLUOROMETHOXY) PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| US-7423158-B2 | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of β-secretase | WYETH (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423158-B2 | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of β-secretase | WYETH (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423158-B2 | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of β-secretase | WYETH (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1928841-A1 | AMINO-5- Ý4- (DIFLUOROMETHOXY) PHENYL¨-5-PHENYLIMIDAZOLONE COMPOUNDS AS INHIBITORS OF THE BETA-SECRETASE (BACE) | Wyeth a Corporation of the State of Delaware (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007038271-A9 | AMINO-5- [4- (DIFLUOROMETHOXY) PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS AS INHIBITORS OF THE BETA-SECRETASE (BACE) | WYETH CORP (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2007038271-A1 | AMINO-5- [4- (DIFLUOROMETHOXY) PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS AS INHIBITORS OF THE BETA-SECRETASE (BACE) | WYETH (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070072925-A1 | Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072925-A1 | Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072925-A1 | Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012139-A1 | AMINO-5-[4-(DIFLUOROMETHOXY) PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE | BACE1, BACE2, APP | TAAR1 3445/4885IDO1 4153/4885AGXT 2158/4885 |
| US-20070072925-A1 | Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase | BACE1, BACE2, APP | TAAR1 3456/4885IDO1 4396/4885AGXT 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.